Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed
Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non–small-cell lung cancer with cyclooxygenase-2 overexpression : CALGB 30801(Alliance)
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat(WX-671)in combination with gemcitabine compared with gemcitabine alone in patients with nonresectable, locally advanced pancreatic cancer
Phase I study of OPB‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription(STAT)3 inhibitor, in patients with refractory solid malignancies
Functional coupling of p38-induced up-regulation of BiP and activation of RNAdependent protein kinase–like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells
Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases
Differential effect on bone lesions of targeting integrins : randomized phase II trial of abituzumab in patients with metastatic castrationresistant prostate cancer
Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial)
Abstract C119 : Investigation of the anti-angiogenic effects of abituzumab in patients with colorectal or ovarian cancer and liver metastases using dynamic contrast-enhanced magnetic resonance imaging(DCEMRI), AACR-NCI-EORTC
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer : the randomised phase I/II POSEIDON trial
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins(intetumumab)in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients:Randomized European Celecoxib Trial (REACT)
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3(avb3)integrin, ±dacarbazine(DTIC)in patients with metastatic melanoma(MM)
A phase II study of celecoxib with irinotecan, 5-fluorouracil, and leucovorin in patients with previously untreated advanced or metastatic colorectal cancer
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α 2 integrin inhibitor E7820 in patients with advanced solid tumors